Does a transperineal approach to prostate biopsy change your treatment plan compared to transrectal?

For example, transperineal biopsies may capture a higher volume of disease. Should this change risk stratification compared to transrectal biopsies? Is ">50% of cores" still the relevant metric? Conversely, transperineal biopsies may increase uncertainty about proximity of disease to the base of the prostate depending on how the pathologist reads the slide.